Zeltiq Announces Save The Date For 2015 Investor Day

PLEASANTON, CA--(Marketwired - August 17, 2015) - ZELTIQ® (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that it will host an investor and analyst day in New York, NY on November 17th 2015 from 9:30 a.m. ET to 12:00 p.m. ET.

The event will focus on the Company's growth initiatives, R&D pipeline and financial outlook. It will also include an interactive physician panel that will provide additional insight on the CoolSculpting technology, recent product launches and new growth opportunities such as the treatment of acne.

Event: ZELTIQ Investor Day
Date: November 17, 2015
Time: 9:30 a.m. ET to 12:00 p.m. ET (Registration begins at 9:00 a.m. ET)
Location: TBD - Midtown Manhattan, New York, NY

Please RSVP to RSVP@zeltiq.com. The Company will issue an additional press release with further details regarding the event.

An audio webcast of the presentation will be available by visiting the investor relations section of ZELTIQ's web site at www.coolsculpting.com. A replay of the presentation will be available for 90 days.

About ZELTIQ® Aesthetics
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.




Help employers find you! Check out all the jobs and post your resume.

Back to news